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Abstract 
Sheep brucellosis is a worldwide extended disease caused by B. melitensis and B. ovis, two species respectively 
carrying smooth or rough lipopolysaccharide. Vaccine B. melitensis Rev1 is used against B. melitensis and B. ovis but 
induces an anti‑smooth‑lipopolysaccharide response interfering with B. melitensis serodiagnosis, which precludes 
its use against B. ovis where B. melitensis is absent. In mice, Rev1 deleted in wbkC (Brucella lipopolysaccharide formyl‑
transferase) and carrying wbdR (E. coli acetyl‑transferase) triggered antibodies that could be differentiated from those 
evoked by wild‑type strains, was comparatively attenuated and protected against B. ovis, suggesting its potential as a 
B. ovis vaccine.
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Introduction
Brucellosis is one of the most common zoonoses world-
wide, causing significant loss to animal production and 
severely affecting human health [1]. The etiological 
agents of brucellosis are Gram-negative bacteria of the 
genus Brucella. This genus includes several zoonotic spe-
cies among which B. abortus preferentially infects cattle, 
B.  suis swine and wild-life and B. melitensis goats and 
sheep [2]. Sheep can also be infected by B. ovis, a non-
zoonotic species [2]. These species are smooth (S) or 
rough (R), depending on the presence or absence respec-
tively of O-polysaccharide (O-PS) chains in the outer 
membrane lipopolysaccharide (LPS). Whereas B. abor-
tus, B. melitensis and B. suis carry a S-LPS, B. ovis is a 
naturally a R species [2].
B. ovis infection causes genital lesions and reduced 
fertility constituting one of the most important causes 
of reproductive failure in sheep [3]. Animal vaccination 
is the most suitable method for controlling brucellosis 
in areas with moderate to high prevalence of the disease. 
Currently, no specific vaccines against B. ovis infec-
tion are available, but the S live attenuated B. melitensis 
Rev1 vaccine, widely used for vaccination against ovine 
and caprine brucellosis caused by B. melitensis, is also 
effective against B. ovis [4]. However, Rev1 is virulent in 
humans, induces abortions when used in pregnant ani-
mals [4] and is resistant to streptomycin, an antibiotic of 
choice for brucellosis treatment [5]. While these prob-
lems can be solved by using appropriate vaccination strat-
egies and biosafety precautions [4, 6], Rev1 also induces a 
strong antibody response to the O-PS section of S-LPS 
[7] thus hampering differentiation between true infected 
and vaccinated animals (DIVA problem) in the routine 
diagnosis of B. melitensis. Because of this, Rev1 is banned 
in the countries where B. melitensis has been eradicated, 
resulting in a subsequent increase in B. ovis infections in 
sheep. Since B. ovis is naturally R, some attempts to cir-
cumvent the problems associated with Rev1 vaccination 
in B. melitensis-free areas have been based on the use of 
B. ovis. Accordingly, some investigations have examined 
subcellular vaccines carrying B. ovis fractions rich in 
envelope components in lipid-muramyl dipeptide or nan-
oparticle adjuvants [8, 9]. However, these formulations 
either provide less protection than Rev1 or become too 
costly. Also, B. ovis mutants in LPS core genes [10] have 
been explored with promising results. Similarly, a mutant 
in putative ABC transporter encapsulated in alginate 
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has been proposed as B. ovis vaccine [11, 12]. Yet, indus-
trial production of these vaccines would require solv-
ing the problem posed by B. ovis  CO2-dependence [13] 
with the subsequent reassessment of their properties. 
Moreover the ABC transporter mutant requires encap-
sulation [12]. R mutants of S Brucella species (i.e., the 
so-called R vaccines) are more easily produced and, as 
they lack the O-PS, are often assumed to solve the Rev1 
DIVA problem. However, R vaccines still interfere in 
S-LPS ELISA [14–16] because of the cross-reactivity 
with the core epitopes shared by the S and R-LPS or, in 
the wzm/wzt and related B. melitensis 115 spontaneous 
R mutants, presence of a cytoplasm O-PS precursor [17–
19]. Another approach was to delete protein BP26. How-
ever, whereas the BP26-deleted Rev1 provides protection 
against B. ovis, the ancillary BP26 ELISA lacks adequate 
diagnostic sensitivity [20, 21]. More recently, a Rev1 con-
struct expressing the green fluorescent protein as a tag-
ging antigen has been proposed. However, this method 
requires the simultaneous injection of this protein and 
a booster injection to trigger antibody persisting in the 
ancillary ELISA‐green fluorescent protein DIVA test [22].
The aim of this research is to investigate an alternative 
to circumvent the serological diagnosis problems caused 
by the Rev1 vaccine while keeping its good attenuation 
and protection characteristics. Our approach differs from 
those summarized above in that, instead of deleting S 
Brucella antigens or epitopes or introducing a foreign 
antigen, we have modified a Brucella immunodominant 
antigen. For this purpose, we applied to Rev1 the strat-
egy proposed by Martínez-Gómez et  al. [23] to modify 
the epitopic structure of Brucella S-LPS by substituting 
the N-formyl-perosamine of the O-PS by N-acetyl-pero-
samine. We present here the experiments carried out in 
the mouse model as a first step to investigate the validity 
of this approach.
Materials and methods
Bacterial strains and growth conditions
The bacterial strains and plasmids used are listed in 
Additional file 1. For construction of mutants, B. meliten-
sis 16 M and Rev1 strains were grown at 37 °C in tryptic 
soy broth (TSB, Biomérieux, Marcy l’Etoile, France) or in 
this medium supplemented with agar (TSA, Pronadisa, 
Conda, Spain). B. ovis strains were grown at 37 °C in TSB 
supplemented with 0.5% yeast extract (Pronadisa, Conda, 
Spain) and 5% fetal bovine serum (TYSB-S) or this 
medium supplemented with agar (TYSA-S). For the stud-
ies in mice, vaccines and challenge strain were grown in 
Blood Agar Base (BAB, Oxoid) or BAB-S (supplemented 
with 5% fetal bovine serum). Where needed, media were 
supplemented with 5% sucrose (Sigma), diaminopimelic 
acid (DAP; 1  mM), 0.2% activated charcoal (Sigma), 
kanamycin (Km) at 50 µg/mL, chloramphenicol (Cm) at 
20  µg/mL, ampicillin (Amp) at 100  µg/mL, polymyxin 
(Pmx) at 1.5  µg/mL or streptomycin (Strp) at 2.5  µg/
mL. All strains were stored at −80  °C in skimmed milk 
(Scharlau, Barcelona, Spain) or TYSB-7% dimethylsulfox-
ide (DMSO).
DNA manipulations
Plasmid and chromosomal DNA were extracted with 
 Q1Aprep® spin Miniprep Kit (Qiagen GmbH, Hilden, 
Germany) and Ultraclean Microbial DNA Isolation 
Kit (Mo Bio Laboratories), respectively. When needed, 
DNA was purified from agarose gels using a QIAquick 
Gel extraction kit (Qiagen). DNA sequencing was per-
formed by “Servicio de Secuenciación del Centro de 
Investigación Médica Aplicada” (Pamplona, Spain). Prim-
ers were synthesized by Sigma-Genosys Ltd. (Haverhill, 
United Kingdom).
Construction of mutants
For the construction of Rev1::Tn7wbdRKmR mutants, we 
used the plasmid pYRI-27 (pUC18R6KT-miniTn7T-Km-
PwbdR) described in Martínez-Gómez et  al. [23]. The 
acquisition of this vector by Brucella after tetra-paren-
tal mating with conjugative E. coli S17.1 λpir and E. coli 
HB101 (pRK2013) and E. coli SM10 λpir (pTNS2) was 
selected by Km and Pmx resistance. The correct insertion 
and orientation of the miniTn7 carrying wbdR was exam-
ined by PCR as previously described [23].
To obtain a wbdR construct with no Km resist-
ance (Rev1::Tn7wbdR), we used the plasmid pRCI-65 
 (pNPTS138CmRΔKm) described in Martínez-Gómez 
et al. [23]. This suicide plasmid containing the KmR dele-
tion allele was transformed into E. coli β2150, a diami-
nopimelic acid (DAP) auxotrophic donor strain, to avoid 
the use of antibiotic during the conjugation process [24] 
and transferred into Rev1::Tn7wbdRKmR by conjugation. 
The integration of the suicide vector and disruption of 
the target gene were selected by Km sensitivity and con-
firmed by PCR using oligonucleotides KmR-F1 and KmR-
R4 (Additional file 2).
Rev1::Tn7wbdRΔwbkC was constructed in a similar 
way. The suicide plasmid pYRI-31 (pJQKmΔwbkC) [23] 
was used to delete the wbkC gene of Rev1::Tn7wbdR by 
allelic change. The resulting mutator plasmid was intro-
duced in Rev1::Tn7wbdR by conjugation using the E. 
coli β2150. The loss of the plasmid concomitant with the 
deletion of wbkC gene was checked by PCR using oligo-
nucleotides wbkC-F1 and wbkC-R4 (Additional file 2).
The strain B. ovis PA-KmR, used as challenge in 
mouse experiments (see below), was obtained using the 
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modified miniTn7 site-specific integration vector tech-
nology [25, 26].
Characterization of the mutants
Mutants were characterized by the standard Brucella 
typing procedures described in Alton et  al. [27]: colo-
nial morphology, urease, susceptibility to thionine blue, 
fuchsine and safranine, acriflavine agglutination, crystal 
violet dye exclusion test (S/R colony morphology), agglu-
tination with anti-A and anti-M monospecific sera, and 
sensitivity to phages. For co-agglutination, bacteria resus-
pended in 25 µL of saline on a glass slide were mixed with 
an equal amount staphylococci sensitized with anti-For-
myl-Acetyl, anti-Acetyl and anti-Formyl sera, as previ-
ously described [23].
LPS extraction
LPS from Rev1 and Rev1 wbdR tagged was obtained by 
the proteinase-K sodium dodecyl sulfate (SDS) protocol 
[28, 29] with some modifications. Briefly, cells inactivated 
with phenol were suspended in 2% SDS-60 mM Tris–HCl 
buffer (pH 6.8), heated at 100 °C for 10 min and treated 
with proteinase K (60 µL of a 2.5 mg/mL stock per each 
mL of suspension, 3 h at 55 °C). This was followed by two 
consecutive precipitations with 3 volumes of methanol 
with 1% sodium acetate-saturated methanol at −20  °C. 
After centrifugation, pellets were resuspended by sonica-
tion in 3 mL of 60 mM HCl-Tris (pH 6.8), digested with 
nucleases and treated again with proteinase K (3  h at 
55  °C). After a third precipitation, the pellet containing 
LPS was recovered in 1 mL of distilled water and frozen.
SDS‑PAGE and Western blots
Samples were mixed 1:1 with Sample buffer 2x (Bio-Rad), 
heated at 100  °C for 10 min, and analyzed in 15% poly-
acrylamide gels in Tris–HCl-glycine and stained by the 
periodate-alkaline silver method [30]. For Western blots, 
LPS were analyzed in SDS-PAGE gel (12% polyacryla-
mide) (see above) and electrotransferred onto nitrocel-
lulose blotting sheets (Amersham- GE Healthcare Life 
Scientific, Germany; 0.45  µm pore size). The polyclonal 
sera used were the following: Anti-S Brucella serum 
(polyclonal serum from a rabbit infected with B. meliten-
sis 16  M and bled at day 45), Formyl-Acetyl serum and 
Acetyl serum. These last two sera were obtained by the 
method described in Martínez-Gómez et al. [23].
Multiplex PCR
To discriminate between Rev1 wbdR tagged strains 
and all known Brucella species and vaccine strains, 
we designed a pair of primers based on the wbdR gene 
and added them to the 8 pairs of primers used in the 
Bruce-ladder assay [31]. These new primers consisted 
of 5´-TGA TGT TTT GGC AGG AAA GA-3′ (wbdR for-
ward) and 5′-TAG CCC CAG GAG CAA ATG TA-3′ (wbdR 
reverse). We designed them with a Tm similar to that of 
the other primers used in the multiplex PCR and ampli-
fying a band of 347 bp that did not prevent the visuali-
zation of the other specific bands of species or vaccine 
strains.
Studies in mice: virulence and protection
Seven-week-old female BALB/C mice (ENVIGO, Har-
lan) were kept in cages in BSL-3 facilities (ES/31-2010-
000132) with water and food al libitum. Procedures 
were in accordance with the current European (direc-
tive 86/609/EEC) and Spanish (RD 53/2013) legislations, 
supervised by the corresponding Ethical Committee 
for Animal Experimentation and authorised by Aragón 
(reports No. 2014-20 and 2014-21) and Navarra (CEEA 
045/12) Governments. For virulence assessment, 
10-mice groups were inoculated intraperitoneally (IP) 
with 1 × 105 or 1 × 108 colony forming units (CFU) of 
the corresponding strain and mean CFU values per 
spleen were determined at 1 (n = 5) and 5 (n = 5) weeks 
after inoculation as described elsewhere [32]. To evalu-
ate the protective efficacy of Rev1::Tn7wbdRΔwbkC vac-
cine, 5-mice groups were vaccinated subcutaneously 
(SC) with two different doses (1 × 105 and 1 × 108 CFU/
mouse). Mice (n = 5) inoculated SC with the Rev1 refer-
ence vaccine (1 × 105 CFU/mouse) or sterile Buffered 
Saline (BSS; 0.85% NaCl, 0.1%  KH2PO4, 0.2%  K2HPO4; 
pH 6.85) were used as effective-vaccine and unvaccinated 
controls, respectively. Four weeks after vaccination, mice 
were challenged IP with 5 × 106 CFU/mouse of B. ovis 
PA-KmR and the mean CFU/spleen values of this strain 
were determined 2  weeks after. Inocula were prepared 
by harvesting the BAB or BAB-S grown bacteria in sterile 
BSS, adjusting spectrophotometrically (600 nm) the bac-
terial suspension and making proper serial tenfold dilu-
tions. Mice were inoculated with 0.1 mL and doses were 
retrospectively assessed by plating inocula countable 
dilutions. Differentiation between challenge and vaccine 
strains was achieved by plating on BAB supplemented 
with streptomycin and BAB-S supplemented with Km 
(incubated in  CO2 atmosphere). Results were expressed 
as the mean  log10 CFU/spleen ± SD (n = 5) of the corre-
sponding mutant or challenge strain and units of protec-
tion were calculated by subtracting the mean  log10 CFU 
values of the vaccine group from those of unvaccinated 
controls. Statistical comparisons were made by one-way 
ANOVA and Fisher’s Protected Least Significant Differ-
ences (PLSD) post hoc tests. The adequate virulence of 
B. ovis PA-KmR challenge strain was proved in a previ-
ous experiment in BALB/c mice by IP infection (5 × 105 
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CFU/mouse) and bacterial spleen counting (in BAB-S 
and BAB-S supplemented with Km) 3 and 8 weeks later. 
This strain showed identical multiplication to that of B. 
ovis PA (not shown).
Enzyme‑linked immunosorbent assay (iELISA)
Serum antibodies of mice inoculated with Rev1 (paren-
tal strain), Rev1::Tn7wbdR, Rev1::Tn7wbdRΔwbkC and 
B. melitensis 16  M (as control) were analyzed using 
an iELISA with wild-type (N-formyl-perosamine) or 
modified (N-acetyl-perosamine) S-LPS as antigens. For 
this, 96-well plates (Thermo Scientific, Waltham, MA, 
USA) were coated by overnight incubation at 4 °C with 
B. melitensis 16  M or Ba::Tn7wbdRΔwbkC S-LPS at 
2.5 µg/mL or 5 µg/mL, respectively, in PBS. Plates were 
washed with PBS-0.05% Tween 20 (and incubated with 
serial dilutions of sera at 37 °C for 30 min. After wash-
ing, antibodies were detected with peroxidase-labeled 
protein G [19] and 2,2′-azino-bis (3-ethylbenzthiazo-
line-6-sulphonic acid) (ABTS)-H2O2. After 15 min, col-
orimetric reactions were read at 405 nm (Multiescanex, 
Thermo Scientific, Waltman, MA, USA). Results are 
expressed as optical density (O.D.) values of tested sera 
after subtracting the O.D. value of the negative control 
(blank well) in the same plate.
Results
Insertion of wbdR into Rev1 genome modifies the epitopic 
structure of the vaccine
To obtain a tagged Rev1 vaccine, we followed two strate-
gies. First, we obtained Rev1::Tn7wbdR inserting wbdR in 
the chromosome II of Rev1 vaccine using the previously 
described Tn7 methodology [8]. Second, we constructed 
a wbdR tagged Rev1 lacking N-formyl-perosamine in its 
O-PS (Rev1::Tn7wbdRΔwbkC) deleting wbkC (the for-
myl transferase gene) from Rev1::Tn7wbdR. As expected, 
these constructs could be differentiated from Rev1, vac-
cine B. abortus S19, or representative strains of wild-type 
B. abortus, B. melitensis and B. ovis by PCR using the 
Multiplex-PCR combining Bruce-ladder and wbdR spe-
cific primers (Figure 1).
Rev1::Tn7wbdR and Rev1::Tn7wbdRΔwbkC were 
identical to the parental strain in colony morphology, 
growth, oxidase and urease tests and dye sensitivity 
Figure 1 wbdR tagged vaccines can be identified by a modified multiplex PCR assay. Identification and differentiation of Brucella species, 
classical vaccines and Rev1 wbdR tagged vaccines by a modified Bruce‑Ladder [31] that includes a new pair of primers based on the wbdR gene 
that amplify a band of 347 bp specific for tagged vaccines. C–(H2O) and PM (1 Kb plus DNA ladder) used as molecular size marker.
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(Additional file  3). Consistent with previous results in 
virulent B. melitensis 16  M [23], Rev1::Tn7wbdR and 
Rev1::Tn7wbdRΔwbkC did not agglutinate with acrifla-
vine and excluded crystal violet, properties character-
istic of strains expressing S-LPS. On the other hand, 
both wbdR tagged strains were sensitive to phage R/C, 
a phage specific for the O-PS-lacking R brucellae [27], a 
phenotype not observed previously on wbdR constructs 
of virulent strains.
The LPS extracts of Rev1::Tn7wbdR and 
Rev1::Tn7wbdRΔwbkC contained the typical R-LPS 
(i.e. low molecular weight) and S-LPS (higher molecu-
lar weight) fractions present in the parental strain (Fig-
ure  2). However, as observed before for their wbdR 
tagged B. melitensis and B. abortus counterparts [23], 
the S-LPS fraction of the wbdR constructs displayed an 
apparent average molecular weight lower than those 
of the parental strains (Figure 2A). To analyze possible 
epitopic changes associated with wbdR tagging, whole 
cells and LPS extracts were tested by co-agglutination 
and Western blot, respectively, using immune sera 
specifically recognizing O-PS carrying only N-formyl-
perosamine (anti-Formyl), both N-formyl-perosamine 
and N-acetyl-perosamine (anti-Formyl-Acetyl) or only 
N-acetyl-perosamine (anti-Acetyl) [23]. Rev1::Tn7wbdR 
co-agglutinated with staphylococci sensitized with 
anti-Formyl-Acetyl, anti-Acetyl and anti-Formyl sera 
showing that its O-PS contained N-acetyl and N-for-
myl-perosamine. In contrast, Rev1::Tn7wbdRΔwbkC 
did not co-agglutinate with anti-Formyl serum, while 
keeping the anti-Formyl-Acetyl and anti-Acetyl reac-
tivity (Additional file  4). Western blots with protein-
ase-K extracted S-LPS (Figure  2B) confirmed the 
epitopic changes and demonstrated that the differences 
in apparent average molecular weight observed by 
SDS-PAGE (Figure  2A) corresponded in fact to O-PS 
heterogeneity.
wbdR tagging decreases the residual virulence of Rev1
We vaccinated BALB/c mice with  105 CFU/mouse (stand-
ard dose for Brucella S vaccines) of Rev1::Tn7wbdR, 
Rev1::Tn7wbdRΔwbkC and Rev1 and determined CFU 
numbers in spleen. One week post-infection, CFU/spleen 
values were significantly lower in mice infected with 
Rev1::Tn7wbdR or Rev1::Tn7wbdRΔwbkC than in those 
infected with Rev1 (Figure 3A). At week 5, though both 
Rev1::Tn7wbdR and Rev1::Tn7wbdRΔwbkC also showed 
lower CFU, only the values of Rev1::Tn7wbdRΔwbkC 
were statistically different (Figure 3A). However, attenu-
ation with respect to Rev1 was clearly observed for both 
tagged vaccines at post-infection weeks 1 and 5 when the 
experiment was carried out with  108 CFU/mouse, the 
dose recommended for R vaccines (Figure 3B).
Mice vaccinated with Rev1 wbdR constructs can be 
discriminated by ELISA
We then analyzed by iELISA the sera of mice vac-
cinated with  108 CFU using first the S-LPS of 
Ba::Tn7wbdRΔwbkC as antigen. As expected, and no 
matter the vaccine, no serum from these mice showed 
ELISA reactivity one week post-infection (not shown). 
At week 5, whereas most sera of mice inoculated with 
the wbdR constructs showed some reactivity, sera of mice 
infected with Rev1 or B. melitensis did not react (Fig-
ure  4A). Interestingly, the reverse picture was obtained 
in the iELISA with wild-type S-LPS as antigen: whereas 
Figure 2 Insertion of wbdR into Rev1 genome modifies the epitopic structure of the vaccine. A SDS‑PAGE electrophoresis‑silver staining and 
B Western blot analyses of SDS‑proteinase K extracts of (1) Rev1, (2) Rev1::Tn7wbdR, and (3) Rev1::Tn7wbdRΔwbkC.
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mice infected with Rev1 or B. melitensis developed react-
ing antibodies, sera of mice inoculated with wbdR con-
structs displayed almost no reaction (Figure  4B) with 
small but consistently repeated (not shown) differences 
between Rev1::Tn7wbdR and Rev1::Tn7wbdRΔwbkC.
Rev1::Tn7wbdRΔwbkC protects against B. ovis in the mouse 
model
Based on the ELISA results and on its lack of reactiv-
ity with the anti-Formyl serum (Additional file  4), we 
chose Rev1::Tn7wbdRΔwbkC to study the efficacy 
of wbdR tagged vaccines against B. ovis. As shown in 
Table  1, this vaccine conferred protection at the two 
A B
Figure 3 wbdR tagging decreases the residual virulence of Rev1. BALB/C mice were inoculated with the indicated doses and CFU/spleen 
determined at post‑infection weeks 1 and 5 (*p < 0.05, **p < 0.01, ***p < 0.001).
A B
Figure 4 Mice vaccinated with Rev1 wbdR constructs can be discriminated by iELISA. The sera of mice obtained 5 weeks after inoculation 
with Rev1, Rev1::Tn7wbdR or Rev1::Tn7wbdRΔwbkC were analyzed by iELISA with N‑acetyl‑perosamine S‑LPS (from a Tn7wbdRΔwbkC construct of B. 
abortus 2308) (A) or N‑formyl‑perosamine S‑LPS (from B. melitensis 16 M) (B). Sera from B. melitensis 16 M‑infected mice were included as a control. 
The serum dilutions used was 1:20 (A) and 1:40 (B).
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doses tested. However, only the  108 CFU/mouse dose 
(used for rough vaccines in the mouse model) con-
ferred a protection similar to Rev1 at the standard dose 
(Table  1). Interestingly, even at this higher dose, the 
vaccine CFU remaining in the spleens was markedly 
lower than those of Rev1 (p < 0.01).
Discussion
The results presented in this work demonstrate that the 
O-PS of vaccine Rev1 can be antigenically tagged by 
genomic insertion of wbdR, the acetyltransferase gene 
involved in the synthesis of the O-PS repeating unit of 
E. coli O157:H7. Using the mouse model, we studied 
the protective capacity of wbdR tagged Rev1 against B. 
ovis and tested an ancillary ELISA DIVA test. In previ-
ous and preliminary experiments, we examined whether 
wbdR tagged brucellae (wbdRΔwbkC) could be used as 
antigen in a simple test similar to the Rose Bengal test 
for brucellosis. However, we observed that the modified 
brucellae had a marked tendency to autoagglutinate, a 
feature that is reminiscent of the autoagglutination typi-
cal of R brucellae [16] and shows profound cell surface 
modifications. For this reason, we ruled out the agglu-
tination test and applied an iELISA using the LPS puri-
fied from a wbdRΔwbkC construct [23] adjusted to 
minimize any cross-reactivity between acety-tagged 
and native O-PS. In this assay, we observed differences 
between the antibodies triggered by wbdR tagged vac-
cines when compared with those triggered by Rev1; 
whereas sera of mice vaccinated with Rev1::Tn7wbdR 
or Rev1::Tn7wbdRΔwbkC showed moderate reaction, 
sera corresponding to the Rev1 vaccinated mice did not 
react. Moreover, when the iELISA with wild-type S-LPS 
was used, contrary to the diagnostically interfering reac-
tion showed by Rev1, the sera of mice inoculated with 
wbdR constructs displayed almost no reaction. In a pre-
vious work, we observed that the LPS of Brucella cross-
reacting E. hermanii serotypes reacts strongly with sera 
from infected cattle [21, 33] which are known to con-
tain an overwhelming majority of antibodies of overlap-
ping C specificities [34]. The O-PS of these E. hermanii 
strains contains N-acetylated perosamine in an α (1–3) 
and α (1–2) linkage frequency and arrangement differ-
ent from those in Rev1 (i.e. B. melitensis biovar 1) and 
cross-react with Brucella M monoclonal antibodies in gel 
immunoprecipitation [33]. The O-PS in the wbdRΔwbkC 
constructs does not react in ELISA with C/Y-A = M or 
al C/Y-A > M in ELISA [23]. These data suggest epitopic 
differences that, in addition to differences in the intensity 
of the stimulus in an experimental infection in mice and 
a natural infection in cattle, in the subsequent different 
avidity of the antibodies and in the standardization of the 
ELISA, could account for these apparently contradictory 
results. Our results suggest that the use of wbdR tagged 
Rev1 and its ancillary ELISA might be a suitable strategy 
to solve the DIVA problem associated with the unmodi-
fied vaccine, but it is clear that experiments in sheep are 
necessary for a definite assessment.
In keeping with previous studies in virulent brucel-
lae [23], the most profound modification was obtained 
in Rev1::Tn7wbdRΔwbkC and, accordingly, we tested its 
protective capacity in the mouse model. We observed 
that a  108 CFU/mouse dose was necessary to reach the 
protection levels obtained with Rev1 at  105 CFU/mouse. 
The recommended dose for brucellosis R vaccines is also 
 108 CFU/mouse [35] and, like the autoagglutination com-
mented above this suggests surface similarities between 
the Rev1::Tn7wbdRΔwbkC construct and R brucellae. 
The lack of O-PS in the latter increases the exposure of 
lipid A-core and Omp charged groups and it has been 
postulated that the OP-S acts as a negative modulator of 
unspecific interactions of these bacteria with host cells, 
thus favoring invasion for specific routes [18]. On these 
bases, it can be hypothesized that either the N-acetyl-
perosamine O-PS cannot replace the N-formyl-perosa-
mine with regards to surface physicochemical properties 
and/or that the shorter O-PS of Rev1::Tn7wbdRΔwbkC 
constructs does not provide enough steric hindrance to 
the Omps and the lipid A-core section, as suggested by 
its sensitivity to the R/C phage. These surface changes 
may account for our observation that, when tested for 
the residual virulence (Figure 3), we found that the CFU 
counts/spleen of Rev1::Tn7wbdRΔwbkC were lower 
than those of Rev1 even at a dose one thousand times 
higher, a result in agreement with the low numbers of 
CFU remaining in the spleens in the vaccination experi-
ments (Table  1). Taken together, these results in mice 
suggest that Rev1::Tn7wbdRΔwbkC could be not only a 
DIVA vaccine but also a vaccine with reduced residual 
virulence in the host. Research is in progress to evaluate 
Table 1 Protection induced by Rev1::Tn7wbdRΔwbkC 
against B. ovis 
Statistical comparison (n = 5) of mean  log10 B. ovis CFU/spleen: ap < 0.001 vs. 
PBS (unvaccinated), bp > 0.05 vs. Rev1 and  log10 vaccine CFU/spleen 
c p < 0.01 vs. 
Rev1.
Vaccine (dose) Mean ± SD of  log10 CFU 
in spleen of:
Units 
of protection
B. ovis Vaccine
Rev1  (105) 2.45 ± 1.35a 2.82 ± 0.99 3.81
Rev1::Tn7wbdRΔwbkC  (105) 4.47 ± 1.40 0.69 ± 0.09c 1.79
Rev1::Tn7wbdRΔwbkC  (108) 2.16 ± 0.95a, b 0.90 ± 0.53c 4.10
PBS (unvaccinated) 6.26 ± 0.16 0.00
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serological response and protective capacity against B. 
ovis of Rev1::Tn7wbdRΔwbkC in sheep.
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